Abstract | OBJECTIVE: This trial evaluated the effect of methylphenidate transdermal system (MTS) on the full spectrum of adult symptoms (attention-disorganization, hyperactivity-impulsivity, emotional dysregulation [ED], and oppositional-defiant disorder [ODD]) found in this disorder. METHOD: This placebo-controlled, double-blind, flexible-dose, crossover trial employed the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) and Connor's Adult ADHD Rating Scale (CAARS) and two measures of adult ODD. Treatment responses of all participants and four subgroups (ADHDalone, ADHD + ED, ADHD + ODD, and ADHD + ED + ODD) were assessed. RESULTS: Around 23% of baseline participants were ADHD alone, 31% were ADHD + ED, 10% were ADHD + ODD, and 36% were ADHD + ED + ODD. There was a significant treatment effect for all symptom areas and all four subgroups. MTS was associated with significantly more adverse events, especially dermatologic side effects. CONCLUSIONS: MTS was effective in treating adult ADHD. This clinical trial included numerous participants meeting criteria for ED and ODD. All ADHD symptoms responded positively to treatment with MTS.
|
Authors | Barrie K Marchant, Frederick W Reimherr, Reid J Robison, John L Olsen, Douglas G Kondo |
Journal | Journal of attention disorders
(J Atten Disord)
Vol. 15
Issue 4
Pg. 295-304
(May 2011)
ISSN: 1557-1246 [Electronic] United States |
PMID | 20410322
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Administration, Cutaneous
- Adult
- Attention Deficit Disorder with Hyperactivity
(drug therapy, psychology)
- Attention Deficit and Disruptive Behavior Disorders
(drug therapy, psychology)
- Cross-Over Studies
- Double-Blind Method
- Emotions
(drug effects)
- Female
- Humans
- Male
- Methylphenidate
(administration & dosage, therapeutic use)
- Treatment Outcome
|